Brigacent 90 mg Tablet should be taken orally, with or without food. Swallow the tablet whole with a glass of water. Do not crush or chew.

Brigacent selectively inhibits cyclooxygenase-2 (COX-2) enzyme, which is responsible for the synthesis of prostaglandins involved in inflammation, pain, and fever. By selectively inhibiting COX-2, it reduces these symptoms with a lower risk of gastrointestinal side effects compared to non-selective NSAIDs.

• •Hypersensitivity to the active substance or to any of the excipients
• •History of asthma, urticaria, or allergic reactions after taking aspirin or other NSAIDs
• •Active peptic ulceration or gastrointestinal bleeding
• •Severe hepatic dysfunction or severe renal impairment (creatinine clearance < 30 mL/min)
• •Congestive heart failure (NYHA Class II-IV)
• •Established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease
• •Third trimester of pregnancy

Store below 30°C in a dry place, away from direct sunlight and moisture. Keep out of reach of children.

In case of an overdose, symptoms may include lethargy, drowsiness, nausea, vomiting, and epigastric pain. Gastrointestinal bleeding can occur. Rarely, hypertension, acute renal failure, respiratory depression, and coma may occur. Management is symptomatic and supportive. There is no specific antidote. Gastric decontamination (e.g., activated charcoal) may be considered within an hour of ingestion.

Pregnancy Category C (first and second trimesters), Category D (third trimester). Brigacent is not recommended in the third trimester of pregnancy due to potential for premature closure of the ductus arteriosus and impaired renal function in the fetus. Use during the first and second trimesters should only be considered if the potential benefit outweighs the potential risk. Brigacent is not recommended during breastfeeding due to potential excretion into breast milk and adverse effects on the infant.